股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 亞盛醫藥集團 | | | | 呈交日期: | 2025年8月6日 | | | | I. 法定/註冊股本變動 | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06855 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,00 ...

Market Overview - On August 5, U.S. stock indices closed lower, with the Dow Jones Industrial Average down 0.14% at 44,111.74 points, the S&P 500 down 0.49% at 6,299.19 points, and the Nasdaq Composite down 0.65% at 20,916.55 points [1] Pharmaceutical Sector - The pharmaceutical sector saw significant gains, with Pfizer rising over 5% and UnitedHealth Group increasing over 4% following President Trump's announcement of potential tariffs on imported drugs [4] - Trump indicated that the initial tariffs would be small, with plans to increase them to 150% within a year and up to 250% thereafter, aiming to encourage domestic drug production [4] Economic Indicators - The ISM reported that the U.S. services PMI for July was 50.1, below market expectations of 51.5 and the previous month's 50.8, indicating near stagnation in service sector growth [1] - Employment indicators dropped from 47.2 to 46.4, marking the lowest level since the COVID-19 pandemic began, while the prices for materials and services surged to 69.9, the highest since October 2022 [1] Technology Sector - Major tech stocks mostly declined, with Meta and Microsoft both down over 1%, while Nvidia fell nearly 1% [2] - Amazon's stock, however, increased by nearly 1% [2] Banking Sector - Most bank stocks also experienced declines, with JPMorgan Chase down nearly 1% and Goldman Sachs down 0.71% [2] Energy Sector - The energy sector saw most stocks rise, with Chevron and Schlumberger both up over 1% [2] Airline Sector - Airline stocks collectively rose, with American Airlines up over 3% and United Airlines up 0.75% [3] Semiconductor Sector - The semiconductor sector faced declines, with the Philadelphia Semiconductor Index down 1.12% [3] - Notable declines included GlobalFoundries down over 9% and TSMC down over 2% [3]

Market Overview - US stock indices opened mixed on August 5, later experiencing a collective drop, with all major indices turning negative by the time of reporting [1] - The Dow Jones Industrial Average closed at 44,004.55, down 169.09 points (-0.38%); the Nasdaq Composite at 20,995.61, down 57.97 points (-0.28%); and the S&P 500 at 6,307.92, down 22.02 points (-0.35%) [2] Chinese Stocks Performance - The Nasdaq China Golden Dragon Index saw a slight increase, with notable gains from several companies: Ascentage Pharma rose nearly 10%, Sohu increased over 6%, and Zhihu and Zai Ding Pharma both rose over 3% [3][4] Corporate Earnings and Stock Movements - Pfizer's stock rose over 5% after reporting Q2 revenue of $14.65 billion, a 10% year-over-year increase, driven by core drug sales growth [6][8] - Palantir Technologies experienced a significant increase of nearly 10%, with a market capitalization exceeding $400 billion, reporting Q2 revenue of $1.004 billion, a 48% year-over-year growth [9][10] - Arteris saw a surge of over 40% in its stock price, attributed to AMD's adoption of its new FlexGen interconnect technology for AI chip design [11][12]

Core Viewpoint - As of August 5, 2023, AAPG's stock price increased by 10.37%, reaching $41.5 per share, with a total market capitalization of $3.858 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a growth of 56.2% year-on-year [1][2]. Company Overview - AAPG is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases. The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [2]. - The company has developed a proprietary platform for protein-protein interaction targeted drug design and is at the forefront of new drug development in the apoptosis pathway. AAPG has established a pipeline of nine Class 1 small molecule new drugs that have entered clinical development [2]. - AAPG's core product, Orebatinib (brand name: Nairike), has been approved in China and is included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022). It has also received various designations from the FDA and the EU [2]. Clinical Development and Collaborations - The company is conducting over 40 clinical trials across China, the United States, Australia, and Europe. It has received 16 FDA orphan drug designations and 2 FDA fast track designations for its investigational drugs [2]. - AAPG has engaged in collaborations with leading biotechnology and pharmaceutical companies and academic institutions, including UNITY, MD Anderson, Mayo Clinic, Dana-Farber Cancer Institute, Merck, AstraZeneca, and Pfizer [2]. - The company has undertaken several national science and technology major projects, including five under the "Major New Drug Creation" initiative, and is committed to enhancing its R&D capabilities and accelerating the clinical development of its product pipeline [2].

Market Overview - US stock indices rebounded, influenced positively by Trump's market support, leading to a 0.68% rise in Hong Kong stocks [1] - San Francisco Fed President Daly indicated that the timing for interest rate cuts is approaching, with expectations for two 25 basis point cuts this year [1] - Goldman Sachs predicts three consecutive 25 basis point cuts starting in September, with a potential 50 basis point cut if unemployment rises further [1] Domestic Market Sentiment - A-share new account openings in July reached 1.96 million, a 71% year-on-year increase, indicating rising domestic confidence [2] - The stock of Upwind New Materials surged 20% after resuming trading, reigniting market enthusiasm [2] - The steel sector saw a significant rise, with Maanshan Iron & Steel's stock increasing over 15% due to improved loss forecasts and supportive policies [2] Industry Trends - The paper industry is experiencing a price increase, with major companies like Nine Dragons Paper and Lee & Man Paper announcing price hikes [2] - The eleventh batch of centralized drug procurement in China saw a record 45 companies applying for the same drug, intensifying competition in the generic drug market [3] - Investment is shifting towards innovative drugs, with companies like Junshi Biosciences seeing stock increases of nearly 34% due to promising clinical trials [3] Financial Support for Key Industries - A joint guideline from the central bank and seven departments aims to support financing for key manufacturing sectors, including integrated circuits and medical equipment [4] - AI-related companies like Longi Green Energy and Lenovo's server business are seeing stock increases due to new orders and market interest [4] Gaming Industry Performance - The domestic gaming market is projected to reach RMB 168 billion in sales by the first half of 2025, a 14.08% year-on-year increase [4] - Heartbeat Games anticipates a revenue increase of approximately 37% for the first half of 2025, driven by strong performance from self-developed games [4] Individual Company Highlights - Tencent's mobile game "Valorant: Source Action" is set to launch on August 19, with projected annual revenue exceeding RMB 6 billion [5] - Oriental Selection's stock surged nearly 17% ahead of its upcoming financial report, reflecting strong market performance [6] - The Macau gaming sector is experiencing a positive trend, with Morgan Stanley raising its revenue growth forecast for the year from 5% to 10% [6] Technological Advancements - Apple's breakthrough in brain-computer interface (BCI) technology allows users to control devices through thought, indicating a significant market opportunity [7] - The Chinese BCI market is expected to exceed RMB 3.8 billion by 2025, with a CAGR of approximately 20% [7] Investment Opportunities - Kelun-Bio has become a top holding in a major fund, indicating strong market confidence in its innovative drug pipeline [8] - The company has established multiple technology platforms and is expected to accelerate commercialization in 2025 [8]

Group 1 - The core viewpoint is that there is a resurgence of Chinese companies listing in the US, with 50 companies successfully going public, marking a significant increase and reflecting a new strategy for Chinese enterprises in the global capital market [1][2] - The number of Chinese companies listed in the US has increased by 78.57% compared to the same period last year, with 23 companies listed in the first quarter alone, accounting for 26.4% of new listings on US stock exchanges [2] - The listing trend has shifted from a focus on the internet sector to a more diverse range of industries, with 14 companies from the industrial sector and 12 from the consumer sector, indicating a broader representation of Chinese enterprises [2] Group 2 - Hong Kong has emerged as the primary hub for Chinese companies listing in the US due to its unique geographical advantages, serving as a bridge between mainland China and global capital markets [4] - Many mainland companies establish a presence in Hong Kong before listing in the US, allowing them to navigate complex regulatory requirements more effectively and enhancing international investor confidence [4] Group 3 - The motivation for Chinese companies to list in the US has evolved from merely seeking funds to pursuing a global strategy, leveraging the high liquidity and broad investor base of the US capital market [6] - Companies are adopting more flexible listing strategies, with 77.5% of Chinese companies choosing to issue shares at around $4, which helps increase the success rate of listings and leaves room for future financing [6] Group 4 - Despite the current listing boom, Chinese companies face challenges such as regulatory differences between China and the US and market volatility, prompting a reevaluation of the traditional view that listing is the end goal [8] - The role of Hong Kong as a key output location for Chinese companies is expected to strengthen with the facilitation of cross-border capital flows, potentially leading to more companies utilizing the "Hong Kong + US" dual-platform model for growth [8]

Group 1 - The core viewpoint of the articles highlights the significant growth and activity in the Hong Kong innovative drug sector, with the Hong Kong Innovative Drug 50 ETF (513780) experiencing a year-to-date increase of approximately 100% [1] - Notable individual stocks in the innovative drug sector include Ascentage Pharma-B, which rose over 10%, and others like CanSino Biologics and Lepu Biopharma-B, which increased by more than 7% [1] - The net inflow of funds into the Hong Kong Innovative Drug 50 ETF has been substantial, with a total net inflow of 526 million yuan over the last nine trading days and over 800 million yuan in the past three months, indicating accelerated capital deployment [1] Group 2 - The top ten constituents of the CSI Hong Kong Stock Connect Innovative Drug Index account for a cumulative weight of 70.19%, including high-quality A-share companies like Innovent Biologics and CSPC Pharmaceutical Group [2] - The innovative drug sector in China is at a new historical starting point, with domestic companies enhancing their competitiveness and expanding overseas, while industry revenue is rapidly growing and moving towards a profit-driven new cycle [2] - Strong policy support is crucial for the development of the innovative drug industry, providing a favorable environment for growth and investment opportunities [2]

（文章来源：每日经济新闻） 每经AI快讯，港股创新药板块继续走强，亚盛医药-B涨逾10%，康诺亚-B、乐普生物-B涨逾7%，诺诚 健华、信达生物涨超5%。 ...

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

Group 1 - The Hong Kong biotechnology sector experienced a rise on August 5, with notable increases in stock prices for several companies [1] - Gilead Sciences (歌礼制药) saw a surge of over 15% in its stock price [1] - Ascentage Pharma (亚盛医药) increased by more than 9% [1] - Other companies such as Jiahe Biopharma (嘉和生物) and Innovent Biologics (复宏汉霖) rose by over 8% [1] - CanSino Biologics (康希诺生物) and Zai Lab (再鼎医药) experienced increases of over 5% [1]